Israel · Delayed Price · Currency is ILS · Price in ILA BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of ILS 34.07 million. The enterprise value is 27.26 million.
| Market Cap | 34.07M |
| Enterprise Value | 27.26M |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.62 billion shares outstanding. The number of shares has increased by 49.35% in one year.
| Current Share Class | 2.62B |
| Shares Outstanding | 2.62B |
| Shares Change (YoY) | +49.35% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 4.39% |
| Float | 2.46B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.22 |
| PB Ratio | 0.69 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.20 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.73 |
| Interest Coverage | -12.01 |
Financial Efficiency
Return on equity (ROE) is -55.27% and return on invested capital (ROIC) is -26.58%.
| Return on Equity (ROE) | -55.27% |
| Return on Assets (ROA) | -19.82% |
| Return on Invested Capital (ROIC) | -26.58% |
| Return on Capital Employed (ROCE) | -61.46% |
| Weighted Average Cost of Capital (WACC) | 8.90% |
| Revenue Per Employee | 188,496 |
| Profits Per Employee | -946,406 |
| Employee Count | 24 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.10% in the last 52 weeks. The beta is 0.70, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -38.10% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 33.61 |
| Average Volume (20 Days) | 3,854,588 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLineRx had revenue of ILS 4.15 million and -20.82 million in losses. Loss per share was -0.01.
| Revenue | 4.15M |
| Gross Profit | 3.32M |
| Operating Income | -36.26M |
| Pretax Income | -30.21M |
| Net Income | -20.82M |
| EBITDA | -36.10M |
| EBIT | -36.26M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 38.96 million in cash and 23.66 million in debt, with a net cash position of 15.30 million or 0.01 per share.
| Cash & Cash Equivalents | 38.96M |
| Total Debt | 23.66M |
| Net Cash | 15.30M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 49.51M |
| Book Value Per Share | 0.02 |
| Working Capital | 7.95M |
Cash Flow
In the last 12 months, operating cash flow was -32.18 million and capital expenditures -74,478, giving a free cash flow of -32.26 million.
| Operating Cash Flow | -32.18M |
| Capital Expenditures | -74,478 |
| Depreciation & Amortization | 157,625 |
| Net Borrowing | -14.77M |
| Free Cash Flow | -32.26M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 80.03% |
| Operating Margin | -874.28% |
| Pretax Margin | -728.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.35% |
| Shareholder Yield | -49.35% |
| Earnings Yield | -61.11% |
| FCF Yield | -94.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jun 7, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
BioLineRx has an Altman Z-Score of -17.51 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.51 |
| Piotroski F-Score | 2 |